Radiotherapy research changes standard clinical practice and improves survival for patients with small-cell lung cancer

Impact: Health and wellbeing


We led and co-led two international, phase III radiotherapy trials in small-cell lung cancer (SCLC), which changed and standardised routine clinical practice and improved patient survival.
The CONVERT trial led to greater standardisation of chemo-radiotherapy treatment for limited-stage disease and the adoption of an optimised treatment regimen in UK, European and US guidance. The trial also showed that chemo-radiotherapy was a feasible treatment option for patients over 70 years who were previously under-treated.
Following the CREST trial, the number of centres offering thoracic radiotherapy in seven surveyed European countries, including UK, rose from 25% to 81%. Local thoracic radiotherapy treatment has been adopted in UK, European, US and Australian clinical guidelines.
Impact date1 Aug 201331 Dec 2020
Category of impactHealth and wellbeing
Impact levelAdoption

Research Beacons, Institutes and Platforms

  • Cancer
  • Manchester Cancer Research Centre